NP_000851.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
21,526 Da
NCBI Official Full Name
15-hydroxyprostaglandin dehydrogenase
NCBI Official Synonym Full Names
hydroxyprostaglandin dehydrogenase 15-(NAD)
NCBI Official Synonym Symbols
PGDH; PGDH1; PHOAR1; 15-PGDH; SDR36C1 [Similar Products]
NCBI Protein Information
15-hydroxyprostaglandin dehydrogenase [NAD(+)]
UniProt Protein Name
15-hydroxyprostaglandin dehydrogenase [NAD(+)]
UniProt Synonym Protein Names
Prostaglandin dehydrogenase 1; Short chain dehydrogenase/reductase family 36C member 1
UniProt Synonym Gene Names
UniProt Entry Name
PGDH_HUMAN
NCBI Summary for HPGD
This gene encodes a member of the short-chain nonmetalloenzyme alcohol dehydrogenase protein family. The encoded enzyme is responsible for the metabolism of prostaglandins, which function in a variety of physiologic and cellular processes such as inflammation. Mutations in this gene result in primary autosomal recessive hypertrophic osteoarthropathy and cranioosteoarthropathy. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2009]
UniProt Comments for HPGD
HPGD: Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. Defects in HPGD are the cause of hypertrophic osteoarthropathy, primary, autosomal recessive, type 1 (PHOAR1). A disease characterized by digital clubbing, periostosis, acroosteolysis, painful joint enlargement, and variable features of pachydermia that include thickened facial skin and a thickened scalp. Other developmental anomalies include delayed closure of the cranial sutures and congenital heart disease. Defects in HPGD are the cause of cranioosteoarthropathy (COA). A form of osterarthropathy characterized by swelling of the joints, digital clubbing, hyperhidrosis, delayed closure of the fontanels, periostosis, and variable patent ductus arteriosus. Pachydermia is not a prominent feature. Defects in HPGD are a cause of isolated congenital nail clubbing (ICNC); also called clubbing of digits or hereditary acropachy. ICNC is a rare genodermatosis characterized by enlargement of the nail plate and terminal segments of the fingers and toes, resulting from proliferation of the connective tissues between the nail matrix and the distal phalanx. It is usually symmetrical and bilateral (in some cases unilateral). In nail clubbing usually the distal end of the nail matrix is relatively high compared to the proximal end, while the nail plate is complete but its dimensions and diameter more or less vary in comparison to normal. There may be different fingers and toes involved to varying degrees. Some fingers or toes are spared, but the thumbs are almost always involved. Belongs to the short-chain dehydrogenases/reductases (SDR) family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: EC 1.1.1.141; Oxidoreductase; Tumor suppressor
Chromosomal Location of Human Ortholog: 4q34-q35
Cellular Component: cytoplasm; cytosol; nucleoplasm
Molecular Function: 15-hydroxyprostaglandin dehydrogenase (NAD+) activity; catalytic activity; NAD binding; prostaglandin E receptor activity; protein homodimerization activity
Biological Process: female pregnancy; lipoxygenase pathway; negative regulation of cell cycle; ovulation; parturition; prostaglandin metabolic process; transforming growth factor beta receptor signaling pathway
Disease: Digital Clubbing, Isolated Congenital; Hypertrophic Osteoarthropathy, Primary, Autosomal Recessive, 1
Research Articles on HPGD
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-HPGD antibody
Pathways associated with anti-HPGD antibody
Diseases associated with anti-HPGD antibody
Disease Name |
Pubmed Publications |
Osteoarthropathy, Primary Hypertrophic Antibodies |
>23 publications with HPGD and Osteoarthropathy, Primary Hypertrophic |
HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1 Antibodies |
>23 publications with HPGD and HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1 |
Inflammation Antibodies |
>14 publications with HPGD and Inflammation |
Breast Neoplasms Antibodies |
>5 publications with HPGD and Breast Neoplasms |
Pain Antibodies |
>3 publications with HPGD and Pain |
Fibrosis Antibodies |
>3 publications with HPGD and Fibrosis |
Prostatic Neoplasms Antibodies |
>3 publications with HPGD and Prostatic Neoplasms |
Fetal Growth Retardation Antibodies |
>2 publications with HPGD and Fetal Growth Retardation |
Cardiovascular Diseases Antibodies |
>1 publications with HPGD and Cardiovascular Diseases |
Neoplasms, Experimental Antibodies |
>1 publications with HPGD and Neoplasms, Experimental |
Organs/Tissues associated with anti-HPGD antibody
|